Ferritin is a molecule with enormous potentiality in biotechnology that have been already used to encapsulate molecules, as contrast in magnetic resonance imaging and to carry epitopes. We proposed to use it to carry another key protein of iron metabolism, hepcidin that is a small hormone peptide that control systemic iron homeostasis. In this work, we purified the previously produced camel hepcidin and human H-ferritin heteropolymer (HepcH-FTH) and to monitor its binding capability toward J744 cell line in presence or absence of ferric ammonium citrate. Fused camel hepcidin and human H-ferritin monomer (HepcH) as well as the assembled HepcH-FTH heteropolymer (ratio 1:5) was easily purified by a one-step purification using size exclusion chromatography. SDS-PAGE electrophoresis of HepcH, purified from soluble and insoluble fractions, showed a single band of 24 kDa with an estimated purity of at least 90%. The purification yields of HepcH from the soluble and insoluble fractions was, respectively, of about 6.80 and 2 mg/L of bacterial culture. Time curse cellular binding assays of HepcH-FTH revealed its great potential to bind the J774 cells after 15 min of incubation. Furthermore, HepcH-FTH was able to degrade ferroportin, the unique hepcidin receptor, even after 30 min of incubation with J774 cells treated with 100 µM ferric ammonium citrate. In conclusion, we proposed ferritin as a peptide carrier to promote the association of the hybrid HepcH-FTH nanoparticle with a particular type of cell for therapeutic or diagnostic.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Polyacrylamide gel electrophoresis
Camel hepcidin-human ferritin H chain (monomer)
Camel hepcidin-human ferritin H assembled with human ferritin H chain (heteropolymer)
Ferric ammonium citrate
Mackenzie B, Garrick MD (2005) Iron imports. II. Iron uptake at the apical membrane in the intestine. Liver Physiol 289:G981–G986
Beutler E (2006) Hemochromatosis: genetics and pathophysiology. Annu Rev Med 57:331–347
Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, Sharma S, Waring A, Ganz T, Elizabeta N (2011) Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 121:4880–4888
Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S (2013) Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest 123:1531–1541
Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD (2013) An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe (−/−) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood 121:1200–1208
Zhen AW, Nguyen NH, Gibert Y, Motola S, Buckett P, Wessling-Resnick M, Fraenkel E, Fraenkel PG (2013) The small molecule genistein increases hepcidin expression in human hepatocytes. Hepatology 58:1315–1325
Michels KR, Zhang Z, Bettina AM, Cagnina RE, Stefanova D, Burdick MD, Vaulont S, Nemeth E, Ganz T, Mehrad B (2017) Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight 2:e92002. https://doi.org/10.1172/jci.insight.92002
Arezes J, Jung G, Gabayan V, Valore E, Ganz T, Bulut Y, Nemeth E (2013) Hepcidin-induced hypoferremia is a host-defense mechanism against siderophilic bacteria. Blood 122:176
Boumaiza M, Carmona F, Poli M, Asperti M, Gianoncelli A, Bertuzzi M, Ruzzenenti P, Arosio P, Marzouki MN (2017) Production and characterization of functional recombinant hybrid heteropolymers of camel hepcidin and human ferritin H and L chains. Protein Eng Des Sel 30:77–84
Xiao JJ, Krzyzanski W, Wang Y-M, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ (2010) Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 12:646–657
Jordan JB, Poppe L, Haniu M, Arvedson T, Syed R, Li V, Kohno H, Kim H, Schnier PD, Harvey TS, Miranda LP, Cheetham J, Sasu BJ (2009) Hepcidin revisited disulfide connectivity dynamics and structure. J Biol Chem 284:24155–24167
Ha SH, Carson AR, Kim K (2012) Ferritin as a novel reporter gene for photoacoustic molecular imaging. Cytom A 81:910–915
Kanekiyo M, Wei C-J, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong W-P, Wang L, Nabel GJ (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102–106
Wang Z, Xu L, Yu H, Lv P, Lei Z, Zeng Y, Liu G, Cheng T (2019) Ferritin nanocage-based antigen delivery nanoplatforms: epitope engineering for peptide vaccine design. Biomater Sci 7:1794–1800
Gianoncelli A, Bonini SA, Bertuzzi M, Guarienti M, Vezzoli S, Kumar R, Delbarba A, Mastinu A, Sigala S, Spano P, Pani L, Pecorelli S, Memo M (2015) An integrated approach for a structural and functional evaluation of biosimilars: implications for erythropoietin. BioDrugs 29:285–300
Delaby C, Pilard N, Gonçalves AS, Beaumont C, Canonne HF (2005) Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 106:3979–3984
OriginLab-Origin and OriginPro-Data Analysis and Graphing Software (n.d.) https://www.originlab.com/. Accessed 26 July 2019
Gagliardo B, Faye A, Jaouen M, Deschemin J-C, Canonne-Hergaux F, Vaulont S, Sari M-A (2008) Production of biologically active forms of recombinant hepcidin, the iron-regulatory hormone. FEBS J 275:3793–3803
Boumaiza M, Jaouen M, Deschemin J-C, Ezzine A, Ben Khalaf N, Vaulont S, Marzouki MN, Sari M-A (2015) Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1. Protein Expr Purif 115:11–18
Dehal PK, Livingston CF, Dunn CG, Buick R, Luxton R, Pritchard DJ (2010) Magnetizable antibody-like proteins. Biotechnol J 5:596–604
Jeon JO, Kim S, Choi E, Shin K, Cha K, So I-S, Kim S-J, Jun E, Kim D, Ahn HJ, Lee B-H, Lee S-H, Kim I-S (2013) Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity. ACS Nano 7:7462–7471
Schmid F-X (2001) Biological macromolecules: UV–Visible spectrophotometry. In: ELS. American Cancer Society. https://doi.org/10.1038/npg.els.0003142
Boumaiza M, Chahed H, Ezzine A, Jaouen M, Gianoncelli A, Longhi G, Carmona F, Arosio P, Sari M-A, Marzouki MN (2016) Recombinant overexpression of camel hepcidin cDNA in Pichia pastoris: purification and characterization of the polyHis-tagged peptide HepcD-His. J Mol Recognit. https://doi.org/10.1002/jmr.2561
Levi S, Cesareni G, Arosio P, Lorenzetti R, Soria M, Sollazzo M, Albertini A, Cortese R (1987) Characterization of human ferritin H chain synthetized in Escherichia coli. Gene 51:269–274
Huh YS, Kim IH (2003) Purification of fusion ferritin from recombinant E. coli using two-step sonications. Biotechnol Lett 25:993–996
Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M (2003) Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood 102:4191–4197
Arosio P, Cozzi A, Ingrassia R, Levi S, Luzzago A, Ruggeri G, Iacobello C, Santambrogio P, Albertini A (1990) A mutational analysis of the epitopes of recombinant human H-ferritin. Biochim Biophys Acta 1039:197–203
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093
Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Tortig SV, Nakamura MC, Seaman WE (2010) Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA 107:3505–3510
Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, Torti SV (2011) Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS ONE 6:e23800
Chen TT, Li L, Chung D-H, Allen CDC, Torti SV, Torti FM, Cyster JG, Chen C-Y, Brodsky FM, Niemi EC, Nakamura MC, Seaman WE, Daws MR (2005) TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 202:955–965
Todorich B, Zhang X, Slagle-Webb B, Seaman WE, Connor JR (2008) Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem 107:1495–1505
Lin X, Xie J, Niu G, Zhang F, Gao H, Yang M, Quan Q, Aronova MA, Zhang G, Lee S, Leapman R, Chen X (2011) Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett 11:814–819
Falvo E, Tremante E, Fraioli R, Leonetti C, Zamparelli C, Boffi A, Morea V, Ceci P, Giacomini P (2013) Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale 5:12278–12285
Liang M, Fan K, Zhou M, Duan D, Zheng J, Yang D, Feng J, Yan X (2014) H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci USA 111:14900–14905
Boumaiza M, Ezzine A, Jaouen M, Sari M-A, Marzouki MN (2014) Molecular characterization of a novel hepcidin (HepcD) from Camelus dromedarius. Synthetic peptide forms exhibit antibacterial activity. J Pept Sci 20:680–688
Maisetta G, Petruzzelli R, Brancatisano FL, Esin S, Vitali A, Campa M, Batoni G (2010) Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: effect of copper and acidic pH. Peptides 31:1995–2002
Jiang X-F, Liu Z-F, Lin A-F, Xiang L-X, Shao J-Z (2017) Coordination of bactericidal and iron regulatory functions of hepcidin in innate antimicrobial immunity in a zebrafish model. Sci Rep 7:4265. https://doi.org/10.1038/s41598-017-04069-x
Hocquellet A, Le Senechal C, Garbay B (2012) Importance of the disulphide bridges in the antibacterial activity of human hepcidin. Peptides 36:303–307
Gerardi G, Biasiotto G, Santambrogio P, Zanella I, Ingrassia R, Corrado M, Cavadini P, Derosas M, Levi S, Arosio P (2005) Recombinant human hepcidin expressed in Escherichia coli isolates as an iron containing protein. Blood Cells Mol Dis 35:177–181
Hood MI, Skaar EP (2012) Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol 10:525–537
Abdul-Tehrani H, Hudson AJ, Chang YS, Timms AR, Hawkins C, Williams JM, Harrison PM, Guest JR, Andrews SC (1999) Ferritin mutants of Escherichia coli are iron deficient and growth impaired, and fur mutants are iron deficient. J Bacteriol 181:1415–1428
MB was supported by a scholarship (1 month) from’Consorzio Interuniversitario Biotecnologie’ (CIB), Trieste–Italy and the Doctoral School of the National Institute of Applied Sciences and Technology (INSAT), University of Carthage, Tunis–Tunisia. Special thanks for the technical help of Dr. Paola Ruzzenenti at the Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, Brescia, Italy.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Fig. S1 Cellular binding analysis of HepcH-FTH toward J774 cells treated and non-treated with FAC. (A) J774 cells treated with 100 µM FAC. Lane 1 and 2, untreated cells; Lane 3, cells treated with 0.5 µM FTH for 2 h; Lane 4 and 5, cells treated with 0.5 µM HepcD-FTH for 30 min; Lane 6, cells treated with 0.5 µM FTH for 2 h; Lane 7, cells treated with 0.5 µM HepcD-FTH for 2 h. (B) Cells non-treated with FAC. Lane 1, non-treated cells; lane 2, cells treated with 0.5 µM FTH for 30 min; Lane 3 and 4, cells treated with 0.5 µM HepcD-FTH during 30 min; Lane 5, cells treated with 0.5 µM FTH for 2 h; Lane 6 and 7, cells treated with 0.5 µM HepcD-FTH for 2h. (C) Western blot analysis of the J774 cells treated with 0.5 µM HepcH-FTH heteropolymer and FTH, using anti-FTH antibodies (rH02). Lane 1, non-treated cells; Lane 2, cells treated with 6 M guanidine; Lane 3, cells treated with 0.5 µM FTH for 30′; Lane 4, cells treated with 0.5 µM HepcH-FTH for 30′; Lane 5, cells treated with human hepcidin for 30 min; Lane 6, cells treated with FTH for 2 h; Lane 7, cells treated with HepcH-FTH for 2 h; Lane 8, cells treated with human hepcidin for 2 h. (D) Cells treated and non-treated with FAC and incubated in presence of FTH for 30 min and 2 h. NT, non-treated cells (CRT). (TIFF 142 kb)
About this article
Cite this article
Boumaiza, M., Poli, M., Carmona, F. et al. Cellular binding analysis of recombinant hybrid heteropolymer of camel hepcidin and human ferritin H chain. The unexpected human H-ferritin binding to J774 murine macrophage cells. Mol Biol Rep 47, 1265–1273 (2020) doi:10.1007/s11033-019-05234-3
- Camel hepcidin
- Human H-ferritin
- Heteropolymer, FAC
- J774 cells